Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our study found that p70S6K1 plays an important role in gemcitabine chemoresistence. MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our findings revealed a new mechanism underlying gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Recommended CitationLin, Yong; Ge, Xin; Wen, Yiyang; Shi, Zhu-Mei; Chen, Qiu-Dan; Wang, Min; Liu, Ling-Zhi; Jiang, Bing-Hua; and Lu, Yuan, "MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells." (2016). Department of Pathology, Anatomy, and Cell Biology Faculty Papers. Paper 208.
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.